77.5 F
New York
Saturday, July 31, 2021

BeiGene’s [NASDAQ: BGNE] KYPROLIS Gets Approval in China

Must read

Ucommune [NASDAQ: UK] Ink Cooperation Agreement with Beijing Investment Group

Ucommune International Ltd. inked a cooperation agreement with Beijing Investment Group Co., LTD. Beijing Investment is a fully state-owned land developer associated with...

Lion Electric [NYSE: LEV] all Set to Deliver Two Electric Trucks to Green Mountain Power

The Lion Electric Company revealed on Friday that it is preparing to deliver two of its all-electric trucks to Green Mountain Power (GMP)...

Digital Realty [NYSE: DLR] Considering Developing 64 MW Facility in South Korea

Digital Realty Trust, Inc. has shown its intention to build the 64-megawatt facility in Seoul, South Korea. The firm has decided that the...

Why Shares of IZEA Worldwide [NASDAQ: IZEA] Skyrocketing Today?

Shares of IZEA Worldwide, Inc. surged 8.10% at the time of writing on Wednesday. The strong performance of the firm has highlighted the...

BeiGene, Ltd. [NASDAQ: BGNE] disclosed Friday that it has got the authorization from the China National Medical Products Administration (NMPA) for KYPROLIS. KYPROLIS has been approved in China for injection in combination with dexamethasone for the cure of adult sufferers with relapsed or refractory (R/R) multiple myeloma who have got at least two earlier therapies.

The two therapies that sufferers received include proteasome inhibitors and immunomodulatory agents. In addition to this, KYPROLIS is approved by BeiGene in China under a strategic partnership with Amgen. This is the first authorization for KYPROLIS in China. Multiple myeloma is an incurable and highly persistent hematological malignancy. Regrettably, the clinical requirements of sufferers in China with this disease have yet to be fully contented.

Furthermore, the conditional authorization of KYPROLIS was dependent on outcomes from the Phase III study (NCT03029234) in China. The study assesses the efficacy and safety of KYPROLIS plus dexamethasone in 123 sufferers with R/R multiple myeloma. The outcome of the study underscored that the efficacy in Chinese sufferers who had got a median of four prior lines of therapy was generally dependable with that witnessed in the global studies.

Moreover, the safety profile witnessed for Chinese sufferers in this trial was in line with that seen in the global trials assessing KYPROLIS in R/R multiple myeloma. In global studies, the most common unfavorable reactions in the combination therapy studies were anemia, diarrhea, fatigue, hypertension, etc. No new safety risks were discovered based on the evaluation of unfavorable events in Chinese sufferers. The complete authorization is dependent on the results of a confirmatory study.

More articles

Latest article

BIT Mining [NYSE: BTCM] Ink Purchase Agreement to Buy Bitcoin Mining Machine

BIT Mining Limited has inked a purchase agreement to increase the fleet of bitcoin mining machines. As per the new purchase agreement, the...

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Dyadic International, Inc. disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been...

Binance, FTX Cut Leverage Limits on Crypto Futures Trading to 20x

Two major cryptocurrency trading platforms Binance Futures and FTX disclosed on Monday that they both have made a remarkable decision related to the crypto...

TD Holdings [NASDAQ: GLG] Inks Letter of Intent with Guangdong Jinbochuang

TD Holdings, Inc. has inked a letter of intent (LOI) with Guangdong Jinbochuang Special Purpose Vehicle Co., Ltd. and (Jinbochuang) and Hunan Jinmeike...

ASGN [NYSE: ASGN] Acquire IndraSoft Inc

ASGN Incorporated disclosed that it has acquired IndraSoft Inc. IndraSoft Inc has gained recognition as a prominent cybersecurity and digital transformation solutions offeror...

Link Reservations Decides to Accept Bitcoin/Crypto Payments

Link Reservations Inc disclosed Friday that it has decided to start accepting Bitcoin and cryptocurrency payments. This is the major breakthrough for the firm...

Athene [NYSE: ATH] Announces Acquisition of Foundation Home Loans

Athene Holding Ltd. disclosed on Thursday that it has inked a definitive agreement to purchase Foundation Home Loans (FHL). FHL had a £3...

Ping [NYSE: PING] and Anexinet Announces Partnership

Ping Identity Holding Corp. and Anexinet Corporation have both entered into a partnership agreement. The collaboration will integrate Ping Identity’s centralized Identity Access...